Interesting, as we know Paul Hopper used to own Prescient Therapeutics.
CHM are working on totally different stuff tp PTX but could benefit from Cellpryme
the market for Cellpryme could be enormous,so it goes to show how seriously under valued
both PTX and CHM both are currently
Interesting times ahead
Interesting, as we know Paul Hopper used to own Prescient...
Add to My Watchlist
What is My Watchlist?
